The Senescence Markers p16INK4A, p14ARF/p19ARF, and p21 in Organ Development and Homeostasis

Cells. 2022 Jun 19;11(12):1966. doi: 10.3390/cells11121966.

Abstract

It is widely accepted that senescent cells accumulate with aging. They are characterized by replicative arrest and the release of a myriad of factors commonly called the senescence-associated secretory phenotype. Despite the replicative cell cycle arrest, these cells are metabolically active and functional. The release of SASP factors is mostly thought to cause tissue dysfunction and to induce senescence in surrounding cells. As major markers for aging and senescence, p16INK4, p14ARF/p19ARF, and p21 are established. Importantly, senescence is also implicated in development, cancer, and tissue homeostasis. While many markers of senescence have been identified, none are able to unambiguously identify all senescent cells. However, increased levels of the cyclin-dependent kinase inhibitors p16INK4A and p21 are often used to identify cells with senescence-associated phenotypes. We review here the knowledge of senescence, p16INK4A, p14ARF/p19ARF, and p21 in embryonic and postnatal development and potential functions in pathophysiology and homeostasis. The establishment of senolytic therapies with the ultimate goal to improve healthy aging requires care and detailed knowledge about the involvement of senescence and senescence-associated proteins in developmental processes and homeostatic mechanism. The review contributes to these topics, summarizes open questions, and provides some directions for future research.

Keywords: SASP; aging; development; endothelial cells; metabolic function; senescence; stem cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cellular Senescence* / genetics
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Homeostasis
  • Tumor Suppressor Protein p14ARF* / metabolism

Substances

  • Biomarkers
  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Protein p14ARF

Grants and funding

This research was funded by Fondation pour la Recherche Medicale, grant number FRM DPC20170139474 (K.-D.W.), Fondation ARC pour la recherche sur le cancer”, grant number n°PJA 20161204650 (N.W.), Gemluc (N.W.), Plan Cancer INSERM (K.-D.W.), and Agence Nationale de la Recherche, grant R19125AA “Senage” (K.-D.W.), Fondation ARC pour la recherche sur le cancer”, grant number n°PJA 20161204650 (K.-D.W.).